Head to head
NeoGenomics vs Thermo Fisher Scientific
Side-by-side on the measures that matter, with a plain-English read. Full detail: NEO · TMO
NEO
NeoGenomics
14.82-1.79%
1-year price shape — +40% over the period
Quant Rating C · 85/100
vs
TMO
Thermo Fisher Scientific
669.54-2.79%
1-year price shape — +17% over the period
Quant Rating C · 61/100
1-year performance, rebased to 100
It’s close.
| NEO | TMO | |
|---|---|---|
| Snapshot | ||
| Sector | Diagnostics & Research | Diagnostics & Research |
| Last price | 14.82 | 669.54 |
| Change today | -1.79% | -2.79% |
| 1-year return | +39.8% | +17.2% |
| Market cap | $1.92B | $248.08B |
| 52-week range | 7.07 – 20.15 | 434.50 – 727.56 |
| Valuation | ||
| P/E (TTM) | -61.75 | 35.31 |
| P/E percentile, own 5-yr range | 5th | 89th |
| P/B | 2.39 | 4.53 |
| Dividend yield | 0.00% | 0.27% |
| Profitability & growth | ||
| EPS (TTM) | -0.84 | 17.74 |
| Net profit (TTM) | $-108.69M | $6.57B |
| Revenue (TTM) | $787.75M | $47.35B |
| Provider revenue period date | 2026-09-29 | 2026-09-25 |
| Revenue growth (YoY) | +11.4% | +9.1% |
| Gross margin | 44.8% | 41.1% |
| Operating margin | -6.2% | 18.7% |
| Net margin | -4.1% | 14.9% |
| Free cash flow (TTM) | $-28.58M | $7.60B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-25 |
| Ownership & sentiment | ||
| Institutional ownership | 116.1% | 94.1% |
| Insider activity (12mo) | 33 buy / 15 sell | 20 buy / 30 sell |
| Short interest (% of float) | 10.2% | 1.3% |
| Analyst consensus | 78% buy / 22% hold (9) | 88% buy / 12% hold (16) |
| Analyst price target | $25 (+67%) | $778 (+16%) |
| StockVane view | ||
| StockVane Quant Rating | C (85) | C (61) |
| Company | ||
| Employees | 2,500 | 125,000 |
| Founded | 1998 | 1956 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.